[
  {
    "id": "Staging Cards 9th Edition 2024_chunk_0",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nLung Cancer T Classiﬁ  cation–9th Edition\nFigure. Courtesy of International Association for the Study of Lung Cancer. Permission must be requested and granted before \nphotocopying or reproducing this material for distribution. Copyright ©2024 Aletta Ann Frazier, MD.\nTumor > 4cm, ≤ 5cm\n(with or without other \nT2 descriptors)Tumor involves main \nbronchus, regardless of \ndistance from carina but \nwithout carinal involvementTumor ≤ 4cm, invasion \nof the visceral pleura\nNote: if the tumor is associated with atelectasis or pneumonitis, \nit is T2a if lesion ≤ 4cm or if tumor size cannot be measured; it is \nT2b if lesion > 4cm, ≤ 5cm.T2a T2b\nTumor > 3cm, ≤ 4cm\nAssociated atelectasis or \nobstructive pneumonitis that \nextends to the hilar region, \neither involving part of the \nlung or the entire lung\nT1a: \nTumor ≤1cm  \nT1b: Tumor \n>1cm, ≤2cmT1c: Tumor\n >2cm, ≤3cm\n    \nTumor ≤3cm; without \nendobronchial extension proximal \nto the lobar bronchusT1a, T1b T1c\nSuperficial spreading tumor of any \nsize with its invasive component \nlimited to the bronchial wall, which \nmay extend proximal to the main \nbronchus, is T1",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 1
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_1",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nLung Cancer T Classiﬁ  cation–9th Edition\nTumor invades parietal pleura or \nchest wall or invades thoracic T1, \nT2 nerve roots, or stellate ganglionTumor > 5cm, ≤ 7cm\nSeparate tumor nodule(s) in \nthe lobe of the primaryT3\nInvasion \nof parietal \n   pleura\nDiaphragmatic\ninvasionTumor involves \ncarinaTumor invades trachea \nand/or SVC or other \ngreat vessel\nTumor > 7cm\nTumor invades\nadjacent\nvertebral bodyTumour invades mediastinum, \nthymus, heart, vagus nerve, \nrecurrent laryngeal nerve,   \nesophagus or diaphragmT4\nTumor accompanied \nby ipsilateral, separate \ntumor nodules, \ndiﬀ  erent lobeTumor that invades \nsubclavian vessels, \nvertebral body, \nlamina, spinal canal, \ncervical nerve roots, \nor brachial plexus\nVan Schil PE, Asamura H, Nishimura KK, et al. The IASLC lung cancer staging project: Proposals for the revisions of the T \ndescriptors in the forthcoming ninth edition of the TNM classification for lung cancer. J Thorac Oncol. 2024; 19(5):749-765.Invasion of the \nazygos vein, \nphrenic nerve, or \npericardium",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 2
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_2",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nLung Cancer N Classiﬁ  cation–9th Edition\nFigure. Courtesy of International Association for the Study of Lung Cancer. Permission must be requested and granted before \nphotocopying or reproducing this material for distribution. Copyright ©2024 Aletta Ann Frazier, MD.\nNo regional \nlymph node \nmetastasesMetastasis \nin ipsilateral \nintrapulmonary/\nperibronchial/\nhilar lymph node(s), \nincluding nodal \ninvolvement by \ndirect extensionN0 N1",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 3
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_3",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nLung Cancer N Classiﬁ  cation–9th Edition\nHuang J, Osarogiagbon RU, Giroux DJ, et al. The International Association for the Study of Lung Cancer staging project for lung \ncancer: Proposals for the revision of the N descriptors in the forthcoming ninth edition of the TNM classification for lung cancer. \nJ Thorac Oncol. 2024; 19(5):766-785.\nMetastasis to \nsingle ipsilateral \nmediastinal or \nsubcarinal lymph \nnode stationN2a\nMetastasis to \nmultiple ipsilateral \nmediastinal and/or \nsubcarinal lymph \nnode stationsN2b",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 4
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_4",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nLung Cancer N, M Classiﬁ  cation–9th Edition\nFigure. Courtesy of International Association for the Study of Lung Cancer. Permission must be requested and granted before \nphotocopying or reproducing this material for distribution. Copyright ©2024 Aletta Ann Frazier, MD.Metastasis in \ncontralateral hilar/\nmediastinal/scalene/\nsupraclavicular \nlymph node(s)Metastasis in \nipsilateral scalene/\nsupraclavicular \nlymph node(s)N3\nContralateral, \nseparate\ntumor nodule(s)\nNote: when the pleural (pericardial) eﬀ  usions are negative a/f_t  er multiple microscopic examinations, and \nthe fluid is non-bloody and not an exudate, they should be excluded as a staging descriptor.Malignant pericardial eﬀ  usion/nodule(s)Malignant \npleural eﬀ  usion/\nnodule(s)M1a\nPrimary \ntumor",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 5
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_5",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nLung Cancer M Classiﬁ  cation–9th Edition\nLiverM1b\nSingle extrathoracic \nmetastasis\nM1b\nThis includes \ninvolvement of \na single distant \n(non-regional) \nlymph nodeFong KM, Rosenthal A, Giroux DJ, et al. The International \nAssociation for the Study of Lung Cancer staging project for \nlung cancer: Proposals for the revision of the M descriptors \nin the forthcoming ninth edition of the TNM classification of \nlung cancer. J Thorac Oncol. 2024; 19(5):786-802.",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 6
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_6",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nLung Cancer M Classiﬁ  cation–9th Edition\nFigure. Courtesy of International Association for the Study of Lung Cancer. Permission must be requested and granted before \nphotocopying or reproducing this material for distribution. Copyright ©2024 Aletta Ann Frazier, MD.Fong KM, Rosenthal A, Giroux DJ, et al. The International Association for the Study of Lung Cancer staging project for lung \ncancer: Proposals for the revision of the M descriptors in the forthcoming ninth edition of the TNM classification of lung cancer. \nJ Thorac Oncol. 2024; 19(5):786-802.\nM1c2\nM1c1\nMultiple \nliver \nmetastases\nLiverBrain\nLymph\nnodes\nBone\nAdrenalMultiple \nextrathoracic\nmetastases \nin multiple\norgan systemsMultiple \nextrathoracic\nmetastases in \na single organ \nsystemAn organ system denotes \nall sites of an organ that is \ndistributed in the body (e.g. \nthe skeletal system, skin, \nextrathoracic lymphatic \nsystem) or of a paired organ \n(e.g. adrenal, kidney)",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 7
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_7",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nLung TNM Deﬁ  nitions–9th Edition\nT: Primary tumor\nTx Primary tumor cannot be assesseda\nT0 No evidence of primary tumor\nTis Carcinoma in situb\nT1 Tumor surrounded by lung or visceral pleura, or in a \nlobar or more peripheral bronchusc\n  T1mi      Minimally invasive adenocarcinomad\n   T1a      Tumor ≤1 cm in greatest dimension\n   T1b      Tumor >1 cm but ≤2 cm in greatest dimension\n   T1c      Tumor >2 cm but ≤3 cm in greatest dimension\nT2 Tumor with any of the following features:\n   T2a • tumor >3 cm but ≤4 cm in greatest dimension;\n• invades visceral pleura; \n• invades an adjacent lobe;\n• involves main bronchus (up to but not including the \ncarina) or is associated with atelectasis or obstruc-\ntive pneumonitis extending to the hilar region, \ninvolving either part of or the entire lung\n   T2b Tumor >4 cm but ≤5 cm in greatest dimension\nT3 Tumor with any of the following features: \n• tumor >5 cm but ≤7 cm in greatest dimension;\n• invades parietal pleura or chest wall;\n• invades pericardium, phrenic nerve, or azygos vein;e\n• invades thoracic nerve roots (i.e. T1, T2) or stellate \nganglion; \n• separate tumor nodule(s) in the same lobe as the \nprimary\nT4 Tumor with any of the following features: \n• tumor >7 cm in greatest dimension;\n• invades mediastinum, thymus, trachea, carina, \nrecurrent laryngeal nerve, vagus nerve, esophagus \nor diaphragm; \n• invades heart, great vessels (aorta, superior/inferior \nvena cava, intrapericardial pulmonary arteries/\nveins), supra-aortic arteries, or brachiocephalic \nveins;\n• invades subclavian vessels, vertebral body, lamina, \nspinal canal, cervical nerve roots, or brachial plexus \n(i.e. trunks, divisions, cords, or terminal nerves); \n• separate tumor nodule(s) in a diﬀ  erent ipsilateral \nlobe than that of the primary a This includes tumors proven by the presence of malignant cells \nin sputum or bronchial washings but not visualized by imaging or \nbronchoscopy.\nb This includes adenocarcinoma in situ – Tis (AIS) – and squamous \ncell carcinoma in situ – Tis (SCIS).\nc The uncommon superﬁ  cial spreading tumor of any size with its \ninvasive component limited to the bronchial wall, which may extend \nproximal to the main bronchus, is also classiﬁ  ed as T1a.\nd Solitary adenocarcinoma (not more than 3 cm in greatest dimen-\nsion), with a predominantly lepidic pattern and not more than 5 mm \ninvasion in greatest dimension. \ne Although these structures lie within the mediastinum, the degree \nof mediastinal penetration by the tumor needed to invade these \nstructures is not counted as T4.N: Regional Lymph Nodes\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in ipsilateral peribronchial and/or ipsilateral \nhilar and/or intrapulmonary lymph nodes, including \ninvolvement by direct extension\nN2 Metastasis in ipsilateral mediastinal and/or subcarinal \nlymph node(s)\nN2a – Single N2 station involvement\nN2b – Multiple N2 station involvement\nN3 Metastasis in contralateral mediastinal, contralateral \nhilar, ipsilateral or contralateral scalene or supraclavicular \nlymph node(s)\nM: Distant Metastasis\nM0 No distant metastasis\nM1 Distant metastasis\nM1a Tumor with pleural or pericardial nodules or malignant \npleural or pericardial eﬀ  usions, separate tumor nodule(s) \nin a contralateral lobe\nM1b Single extrathoracic metastasis in a single organ system\nM1c Multiple extrathoracic metastases\nM1c1 Multiple extrathoracic metastases in a single organ \nsystem\nM1c2 Multiple extrathoracic metastases in multiple organ \nsystems",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 8
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_8",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nNodal Chart–9th Edition\nSUPERIOR MEDIASTINAL NODES\nAORTIC NODES\nINFERIOR MEDIASTINAL NODES\nN1 NODES1 Low cervical, supraclavicular, \n    and sternal notch nodes\n2R Upper Paratracheal (right)\n2L Upper Paratracheal (le/f_t  )\n3a  Prevascular\n3p Retrotracheal\n4R Lower Paratracheal (right)\n4L Lower Paratracheal (le/f_t  )\n5 Subaortic\n6 Para-aortic (ascending aorta or phrenic)\n7 Subcarinal\n8 Paraesophageal (below carina)\n9 Pulmonary ligament \n10 Hilar\n11 Interlobar \n12 Lobar\n13 Segmental \n14 SubsegmentalSupraclavicular zone\nUpper zone\nAP zone\nSubcarinal zone\nLower zone\nHilar/Interlobar zone\nPeripheral zone",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 9
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_9",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nIASLC Nodal Deﬁ  nitions–9th Edition\n#1 (Left/Right) Low cervical, supraclavicular and \nsternal notch nodes\nUpper border: Lower margin of cricoid cartilage\nLower border: Clavicles bilaterally and, in the midline, the upper \nborder of the manubrium\n#L1 and #R1 limited by the midline of the trachea.\n#2 (Left/Right) Upper paratracheal nodes\n2R:Upper border: Apex of lung and pleural space and, in the midline, \nthe upper border of the manubrium\nLower border: Intersection of caudal margin of innominate vein with \nthe trachea\n2L:Upper border: Apex of the lung and pleural space and, in the \nmidline, the upper border of the manubrium\nLower border: Superior border of the aortic arch\nAs for #4, in #2 the oncologic midline is along the left lateral border \nof the trachea.\n#3 Pre-vascular and retrotracheal nodes\n3a: Prevascular – On the right\nUpper border: Apex of chest\nLower border: Level of carina\nAnterior border: Posterior aspect of sternum\nPosterior border: Anterior border of superior vena cava\n3a: Prevascular – On the left\nUpper border: Apex of chest\nLower border: Level of carina\nAnterior border: Posterior aspect of sternum\nPosterior border: Left carotid artery\n3p: Retrotracheal\nUpper border: Apex of chest\nLower border: Carina\n#4 (Left/Right) Lower paratracheal nodes\n4R: Includes right paratracheal nodes, and pretracheal nodes extend-\ning to the left lateral border of trachea\nUpper border: Intersection of caudal margin of innominate vein with \nthe trachea\nLower border: Lower border of azygos vein\n4L: Includes nodes to the left of the left lateral border of the trachea, \nmedial to the ligamentum arteriosum\nUpper border: Upper margin of the aortic arch\nLower border: Upper rim of the left main pulmonary artery\n#5 Subaortic (aorto-pulmonary window)\nSubaortic lymph nodes lateral to the ligamentum arteriosum\nUpper border: The lower border of the aortic arch\nLower border: Upper rim of the left main pulmonary artery#6 Para-aortic nodes (ascending aorta or phrenic)\nLymph nodes anterior and lateral to the ascending aorta and aortic \narch\nUpper border: A line tangential to the upper border of the aortic arch\nLower border: The lower border of the aortic arch\n#7 Subcarinal nodes\nUpper border: The carina of the trachea\nLower border: The upper border of the lower lobe bronchus on the \nleft; the lower border of the bronchus intermedius on the right\n#8 (Left/Right) Para-esophageal nodes (below carina)\nNodes lying adjacent to the wall of the esophagus and to the right or \nleft of the midline, excluding subcarinal nodes\nUpper border: The upper border of the lower lobe bronchus on the \nleft; the lower border of the bronchus intermedius on the right\nLower border: The diaphragm\n#9 (Left/Right) Pulmonary ligament nodes\nNodes lying within the pulmonary ligament\nUpper border: The inferior pulmonary vein\nLower border: The diaphragm\n#10 (Left/Right) Hilar nodes\nIncludes nodes immediately adjacent to the mainstem bronchus and \nhilar vessels including the proximal portions of the pulmonary veins \nand main pulmonary artery\nUpper border: The lower rim of the azygos vein on the right; upper \nrim of the pulmonary artery on the left\nLower border: Interlobar region bilaterally\n#11 Interlobar nodes\nBetween the origin of the lobar bronchi\n*#11s: Between the upper lobe bronchus and bronchus intermedius \non the right\n*#11i: Between the middle and lower lobe bronchi on the right\n*optional sub-categories\n#12 Lobar nodes\nAdjacent to the lobar bronchi\n#13 Segmental nodes\nAdjacent to the segmental bronchi\n#14 Sub-segmental nodes\nAdjacent to the subsegmental bronchi\nRusch VW, Asamura H, Watanabe H, et al. The IASLC lung cancer \nstaging project: A proposal for a new international lymph \nnode map in the forthcoming seventh edition of the TNM \nclassification for lung cancer. J Thorac Oncol. 2009;4:568-577.",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 10
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_10",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nLung Cancer TNM Stages–9th Edition\n1.  Asamura H, Nishimura KK, Giroux DJ, et al. IASLC lung cancer staging project: The new database to inform revisions in the \nninth edition of the TNM classification of lung cancer. J Thorac Oncol. 2023;18(5):564-575.\n2.  Van Schil PE, Asamura H, Nishimura KK, et al. The IASLC lung cancer staging project: Proposals for the revisions of the T \ndescriptors in the forthcoming ninth edition of the TNM classification for lung cancer. J Thorac Oncol. 2024; 19(5):749-765.\n3.  Huang J, Osarogiagbon RU, Giroux DJ, et al. The International Association for the Study of Lung Cancer staging project for \nlung cancer: Proposals for the revision of the N descriptors in the forthcoming ninth edition of the TNM classification for lung \ncancer. J Thorac Oncol. 2024; 19(5):766-785.\n4.  Rusch VW, Asamura H, Watanabe H, et al. The IASLC lung cancer staging project: A proposal for a new international lymph \nnode map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4:568-577.\n5.  Fong KM, Rosenthal A, Giroux DJ, et al. The International Association for the Study of Lung Cancer staging project for lung \ncancer: Proposals for the revision of the M descriptors in the forthcoming ninth edition of the TNM classification of lung \ncancer. J Thorac Oncol. 2024; 19(5):786-802.\n6.  Rami-Porta R, Nishimura KK, Giroux DJ, et al. The International Association for the Study of Lung Cancer lung cancer staging \nproject: Proposals for revision of the TNM stage groups in the forthcoming (ninth) edition of the TNM classification for lung \ncancer. J Thorac Oncol. 2024; 19(7):1007-1027.Stage Groups of the 9th Edition of the Tumor, Node, Metastasis (TNM)\nClassification of Lung Cancer \n9th Edition TNM Descriptors and Stages\nT/M Categories and Descriptors N0 N1N2\nN3 N2a N2b\nT1T1a ≤1 cm IA1 IIA IIB IIIA IIIB\nT1b >1 to ≤2 cm IA2 IIA IIB IIIA IIIB\nT1c >2 to ≤3 cm IA3 IIA IIB IIIA IIIB\nT2T2a Visceral pleura / central invasion IB IIB IIIA IIIB IIIB\nT2a >3 to ≤4 cm IB IIB IIIA IIIB IIIB\nT2b >4 to ≤5 cm IIA IIB IIIA IIIB IIIB\nT3T3 >5 to ≤7 cm IIB IIIA IIIA IIIB IIIC\nT3 Invasion IIB IIIA IIIA IIIB IIIC\nT3 Same lobe separate tumor nodules IIB IIIA IIIA IIIB IIIC\nT4T4 >7 cm IIIA IIIA IIIB IIIB IIIC\nT4 Invasion IIIA IIIA IIIB IIIB IIIC\nT4 Ipsilateral separate tumor nodules IIIA IIIA IIIB IIIB IIIC\nM1M1a Contralateral tumor nodules IVA IVA IVA IVA IVA\nM1a Pleural / pericardial eﬀ  usion, nodules IVA IVA IVA IVA IVA\nM1b Single extrathoracic metastasis IVA IVA IVA IVA IVA\nM1c1 Multiple metastases in 1 organ system IVB IVB IVB IVB IVB\nM1c2 Multiple metastases in >1 organ systems IVB IVB IVB IVB IVB",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 11
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_11",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nIASLC Staging Manual in Thoracic Oncology - download\nFunding support for the 9th Edition of the IASLC Staging Project\nwas generously provided by AstraZenecaScan the QR code to download the \naccompanying Staging Manual in\nThoracic Oncology, 3rd Edition!",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 12
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_12",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nThymic Epithelial Tumors T Classiﬁ  cation–9th Edition\nFigure. Courtesy of International Association for the Study of Lung Cancer. Permission must be requested and granted before \nphotocopying or reproducing this material for distribution. Copyright ©2024 Aletta Ann Frazier, MD.T1\nT2",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 13
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_13",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nThymic Epithelial Tumors T Classiﬁ  cation–9th Edition\nT4T3\nOkumura M, Marino M, Cilento V, et al. The International Association for the Study of Lung Cancer thymic epithelial tumor \nstaging project: Proposal for the T component for the forthcoming ninth edition of the TNM classification of malignant tumors. J \nThorac Oncol. 2023;18(12):1638-1654.",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 14
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_14",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nThymic Epithelial Tumors N Classiﬁ  cation–9th Edition\nFigure. Courtesy of International Association for the Study of Lung Cancer. Permission must be requested and granted before \nphotocopying or reproducing this material for distribution. Copyright ©2024 Aletta Ann Frazier, MD.Fang W, Girard N, Cilento V, et al. The International Association for the Study of Lung Cancer thymic epithelial tumors staging \nproject: Proposals for the N and the M components for the forthcoming ninth edition of the TNM classification of malignant \ntumors. J Thorac Oncol. 2023;19(1):52-70.N1\nN2",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 15
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_15",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nThymic Epithelial Tumors M Classiﬁ  cation–9th Edition\nFang W, Girard N, Cilento V, et al. The International Association for the Study of Lung Cancer thymic epithelial tumors staging \nproject: Proposals for the N and the M components for the forthcoming ninth edition of the TNM classification of malignant \ntumors. J Thorac Oncol. 2023;19(1):52-70.\nM1bM1a",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 16
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_16",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nThymic Epithelial Tumors–9th Edition\nITMIG: International Thymic Malignancy Interest Group. \nFigure. Courtesy of International Association for the Study of Lung Cancer. Permission must be requested and granted before \nphotocopying or reproducing this material for distribution. \nAxial #1 Axial #2ITMIG Mediastinal Compartments\nPrevascular compartment\nVisceral compartment\nParavertebral compartment\nVisceral-paravertebral boundary Ao:  aorta\n PA:  pulmonary artery\n SVC:  superior vena cava\n T:  trachea\n Az:  azygos vein Oes:  esophagus\n RMB:  right main bronchus\n LMB:  le/f_t   main bronchus\n LA:  le/f_t   atrium\n RV:  right ventricle",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 17
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_17",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nThymic Epithelial Tumors–9th Edition\nITMIG Mediastinal Compartments\nPrevascular compartment\nVisceral compartment\nParavertebral compartment\nVisceral-paravertebral boundary Ao:  aorta\n PA:  pulmonary artery\n SVC:  superior vena cava\n T:  trachea\n Az:  azygos vein Oes:  esophagus\n RMB:  right main bronchus\n LMB:  le/f_t   main bronchus\n LA:  le/f_t   atrium\n RV:  right ventricle\nAxial #3 Sagittal\nCarter B, Tomiyama N, Bhora F et al. A Modern Definition of Mediastinal Compartments. J Thorac Oncol. 2014; 9(9): S97-S101.\nITMIG: International Thymic Malignancy Interest Group.",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 18
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_18",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nThymic Epithelial Tumor TNM Deﬁ  nitions–9th Edition\nT category Descriptor*\nT1 A tumor that is limited to the thymus with or \nwithout encapsulation, directly invades into \nthe mediastinal fat only or directly invades the \nmediastinal pleura but does not involve any \nother mediastinal structure.\nT1 is subdivided into\n1. T1a (5 cm or less in its greatest dimension) \n2. T1b (larger than 5 cm in its greatest \ndimension) irrespective of mediastinal \npleura (MP) invasion.\nLevel 1 structures—thymus, anterior mediastinal \nfat, mediastinal pleura\nT2 Tumor directly invades the pericardium (either \npartial or full-thickness), or the lung or the \nphrenic nerve. \nLevel 2 structures—pericardium, lung, phrenic \nnerve\nT3 Tumor directly invades any of the following: \n1) Brachiocephalic vein, 2) Superior vena cava, \n3) Chest wall or 4) Extrapericardial pulmonary \narteries or veins.\nLevel 3 structures—brachiocephalic vein, SVC, \nchest wall, hilar pulmonary vessels\nT4 Tumor directly invades any of the following: \n1) Aorta (ascending, arch, or descending), 2) \nArch vessels, 3) Intrapericardial pulmonary \nartery or veins, 4) Myocardium, 5) Trachea, or \n6) Esophagus.\nLevel 4 structures—aorta (ascending, arch, \nor descending], arch vessels, intrapericardial \npulmonary artery or veins, myocardium, \ntrachea, esophagus)\n*T categories are deﬁ  ned by “levels” of invasion; they reﬂ  ect the highest \ndegree of invasion regardless of how many other (lower level) structures \nare invaded.N category Descriptor*\nN0 No nodal involvement\nN1 Anterior (perithymic) nodes\nN2 Deep intrathoracic or cervical nodes\n* Involvement must be pathologically proven in pathologic staging.\nTNM, tumor, node, metastasis.\nM category Descriptor\nM0 No metastatic pleural, pericardial, or \ndistant sites\nM1 Distant metastasis\nM1a Separate pleural or pericardial nodule(s)\nM1b Pulmonary intraparenchymal nodule or \ndistant organ metastasis*\n*Involvement of non-regional lymph nodes is staged as M1b.\nTNM, tumor, node, metastasis",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 19
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_19",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nThymic Epithelial Tumors TNM Stages–9th Edition\n1. Okumura M, Marino M, Cilento V, et al. The International Association for the Study of Lung Cancer thymic epithelial tumor \nstaging project: Proposal for the T component for the forthcoming (ninth) edition of the TNM classification of malignant tumors. \nJ Thorac Oncol. 2023;18(12):1638-1654. \n2. Fang W, Girard N, Cilento V, et al. The International Association for the Study of Lung Cancer thymic epithelial tumors staging \nproject: Proposals for the N and the M components for the forthcoming (ninth) edition of the TNM classification of malignant \ntumors. J Thorac Oncol. 2023;19(1):52-70. \n3. Ruﬀ  ini E, Huang J, Cilento V. The International Association for the Study of Lung Cancer thymic epithelial tumors staging \nproject: Proposal for a stage classification for the forthcoming (ninth) edition of the TNM classification of malignant tumors. J \nThorac Oncol. 2023;18(12):1655-1671\n4. Marom EM, Fang V, Ruﬀ  ini E. The International Association for the Study of Lung Cancer thymic epithelial tumor staging \nproject: A re-assessment of the International Thymic Malignancy Interest Group/International Association for the Study of Lung \nCancer lymph node map for thymic epithelial tumors for the forthcoming ninth edition of the TNM classification of malignant \ntumors. J Thorac Oncol. 2023;18(12):1672-1688. \n5. Bhora FY, Chen DJ, Detterbeck FC. The ITMIG/IASLC Thymic Epithelial Tumors Staging Project: A Proposed Lymph Node Map \nfor Thymic Epithelial Tumors in the Forthcoming 8th Edition of the TNM Classification of Malignant Tumors. J Thorac Oncol. \n2014;9(9Suppl 2): S88-S96.\n6. Rusch V, Asamura H, Watanabe H. The IASLC lung cancer staging project: A proposal for a new international lymph node map \nin the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4(5):568-577.Stage T category N category M category\nI T1a-b N0 M0\nII T2 N0 M0\nIIIA T3 N0 M0\nIIIB T4 N0 M0\nIVA T any\nT anyN1\nN0,N1M0\nM1a\nIVB T any\nT anyN2\nN anyM0, M1a\nM1b\nNote: any invasion must be histologically conﬁ  rmed for pathologic stage\nTNM, tumor, node, metastasisThymic Epithelial Tumor Stage Groups – 9th Edition",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 20
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_20",
    "text": "ITMIG/IASLC Lymph Node Map\nLower Neck/Cricoid \nCartilage Level \nFigure 1. Lymph node \nlevels at the lower neck, \nbelow the level of the \ncricoid cartilage. N1 \nregion (blue) and N2 \nregion (red). LAC, low \nanterior cervical region; \nP J, peri-jugular region; \nSC, supraclavicular \nregion; T , thyroid\nLower Neck/\nMid Trachea Level\nFigure 2. Lymph node \nlevels at the lower neck, \nmid trachea level. N1 \nregion (blue) and N2 \nregion (red). LAC, low \nanterior cervical region; \nP J, peri-jugular region; \nSC, supraclavicular \nregion; T , thyroid\nAortic Arch Level\nFigure 3. Shaded lymph node groups \nat the level of the aortic arch. N1 \nregion (blue) and N2 region (red). \nIM, internal mammary node group. \nNumbers 3, 4, 6 refer to IASLC node \nmap used for lung cancer.\nLower Neck/Cricoid \nITMIG/IASLC Lymph Node Map\nINTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nThymic Epithelial Tumors–9th Edition",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 21
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_21",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nThymic Epithelial Tumors–9th Edition\nITMIG/IASLC Lymph Node Map\nAorto-Pulmonary Window Level \nFigure 4. Shaded lymph node groups at \nthe level of the aorto-pulmonary window. \nN1 region (blue) and N2 region (red). IM, \ninternal mammary node group. Numbers \n3, 4, 5 refer to IASLC node map used for \nlung cancer.\nMain Pulmonary Artery Level\nFigure 5. Shaded lymph node groups at \nthe level of the main pulmonary artery. \nN1 region (blue) and N2 region (red). IM, \ninternal mammary node group. Numbers \n3, 7, 10R refer to IASLC node map used for \nlung cancer.\nLower Chest (base of the heart) \nLevel\nFigure 6. Native and shaded CT in the \nLower chest demonstrating the anterior \n(perithymic) region (N1)(blue).\nMarom EM, Fang V, Ruﬀ   ini E. The International \nAssociation for the Study of Lung Cancer thymic \nepithelial tumor staging project: A re-assessment \nof the International Thymic Malignancy Interest \nGroup/International Association for the Study \nof Lung Cancer lymph node map for thymic \nepithelial tumors for the forthcoming ninth \nedition of the TNM classification of malignant \ntumors. J Thorac Oncol. 2023;18(12):1672-1688.",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 22
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_22",
    "text": "Gill RR, Nowak AK, Giroux DJ, et al. The International Association for the Study of Lung Cancer mesothelioma staging \nproject: Proposals for revisions of the “T” descriptors in the forthcoming ninth edition of the TNM classification for pleural \nmesothelioma. J Thorac Oncol. 2024;S1556-0864.\nINTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nPleural Mesothelioma T Classiﬁ  cation–9th Edition\nT1 T2\nT3 T4cT2: Tumor involving the ipsilateral pleura with \nPsuma≤12mm and with any of the following:\n•  involvement of the ﬁ  ssure (Fmaxb >5mm)\n•  mediastinal fat invasion\n•  solitary area of chest wall soft tissue invasion;\nor \nTumor involving the ipsilateral pleura with \nPsuma >12mm but ≤30mm, with or without:\n•  involvement of the ﬁ  ssure (Fmaxb >5mm)\n•  mediastinal fat invasion\n•  solitary area of chest wall soft tissue invasion\npT2: Tumor involving the ipsilateral pleura and \nwith any of the following:\n• involvement of the ﬁ  ssure\n• ipsilateral lung parenchyma invasion\n• diaphragm (non-transmural) invasionCLINICAL T (cT)\ncT1: Tumor limited to the \nipsilateral pleura with Psuma\n≤12mm with no involvement of \nthe ﬁ  ssure (Fmaxb≤5mm)\nPATHOLOGICAL T (pT)\npT1: Tumor limited to the \nipsilateral pleura with no \ninvolvement of the ﬁ  ssure\ncT3: Tumor involving the \nipsilateral pleura with Psuma > \n30 mm; with or without: \n•  involvement of the ﬁ  ssure \n(Fmaxb >5mm)\n•  mediastinal fat invasion\n•  solitary area of chest wall \nsoft tissue invasion\npT3: Tumor limited to the \nipsilateral pleura (with or \nwithout ﬁ  ssure involvement) \nand with invasion of any of \nthe following:\n• mediastinal fat\n• surface of pericardium\n•   endothoracic fascia\n• solitary area of chest wall \nsoft tissuecT4: Tumor with invasion of any of the \nfollowing (any Psuma):\n• chest wall bony invasion (rib)\n•  mediastinal organs (heart, spine, \nesophagus, trachea, great vessels)\n• diﬀ  use chest wall invasion \n•  direct tumor extension through the \ndiaphragm or pericardium\n•  direct extension to the contralateral pleura\n•  presence of malignant pericardial eﬀ  usion\npT4: Tumor with invasion of any of the \nfollowing: \n• chest wall bony invasion (rib)\n•  mediastinal organs (heart, spine \nesophagus, trachea, great vessels) \n• diﬀ  use chest wall invasion \n•  transmural invasion of the diaphragm or \npericardium \n•  direct extension to the contralateral pleura\n•  presence of malignant pericardial eﬀ  usion",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 23
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_23",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nPleural Mesothelioma N Classiﬁ  cation–9th Edition\nMetastases to ipsilateral intrathoracic lymph nodes \n(includes ipsilateral bronchopulmonary, hilar, subcarinal, \nparatracheal, aortopulmonary, para-esophageal, \nperidiaphragmatic, pericardial fat pad, intercostal, and \ninternal mammary nodes)\nN2N1\nNodal groups\n• Anterior pericardial fat pad\n• Fat pad adjacent to IVC\n• Posterior intercostal nodes\n• Posterior costophrenic angleLateral N1\nMetastases in the contralateral \nmediastinal, ipsilateral or contralateral \nsupraclavicular lymph nodes\nBillè AR, Ripley RT , Giroux DJ, et al. Proposals for the N descriptors in the forthcoming 9th edition of the TNM classification for \npleural mesothelioma. J Thorac Oncol. in press 2024.\nFigure. Courtesy of International Association for the Study of Lung Cancer. Permission must be requested and granted before \nphotocopying or reproducing this material for distribution.",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 24
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_24",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nPleural Mesothelioma TNM Deﬁ  nitions–9th Edition\nPrimary Tumor (T)\nCategory Clinical T (cT) Pathologic T (pT)\nTx Tumor cannot be assessed \nT0 No tumor is present\nT1 Tumor limited to the ipsilateral pleura with Psuma≤12 \nmm with no involvement of the ﬁ  ssure (Fmaxb≤5 mm)Tumor limited to the ipsilateral pleura with no \ninvolvement of the ﬁ  ssure\nT2 Tumor involving the ipsilateral pleura with Psuma≤12 \nmm and with any of the following:\n• Involvement of the ﬁ  ssure (Fmaxb >5 mm)\n• Mediastinal fat invasion\n• Solitary area of chest wall soft tissue invasion\nor \nTumor involving the ipsilateral pleura with Psuma >12 \nmm but ≤30 mm, with or without:\n• Involvement of the ﬁ  ssure (Fmaxb >5 mm)\n• Mediastinal fat invasion\n• Solitary area of chest wall soft tissue invasionTumor involving the ipsilateral pleura and with any of \nthe following:\n• Involvement of the ﬁ  ssure\n• Ipsilateral lung parenchyma invasion\n• Diaphragm (non-transmural) invasion\nT3 Tumor involving the ipsilateral pleura with Psuma/uni00A0>30 \nmm; with or without:/uni00A0\n• Involvement of the ﬁ  ssure (Fmaxb>5mm)\n• Mediastinal fat invasion\n• Solitary area of chest wall soft tissue invasionTumor limited to the ipsilateral pleura (with or without \nﬁ  ssure involvement) and with invasion of any of the \nfollowing:\n• Mediastinal fat\n• Surface of pericardium\n• Endothoracic fascia\n• Solitary area of chest wall soft tissue\nCategory Clinical T (cT) Pathologic T (pT)\nT4 Tumor with invasion of any of the following (any Psuma):\n• Chest wall bony invasion (rib)\n• Mediastinal organs (heart, spine, esophagus, \ntrachea, great vessels)\n• Diﬀ  use chest wall invasion \n• Direct tumor extension through the diaphragm or \npericardium\n• Direct extension to the contralateral pleura\n• Presence of malignant pericardial eﬀ  usionTumor with invasion of any of the following: \n• Chest wall bony invasion (rib)\n• Mediastinal organs (heart, spine esophagus, trachea, \ngreat vessels) \n• Diﬀ  use chest wall invasion \n• Transmural invasion of the diaphragm or pericardium \n• Direct extension to the contralateral pleura\n• Presence of malignant pericardial eﬀ  usion\na Psum = pmax1 + pmax2 + pmax3 (sum of 3 measurements of maximal pleural thickness measured on axial images along the chest wall or \nmediastinum in each of the three divisions of the chest – upper, middle and lower divided by two lines; one at the top of the aortic arch and \nthe second drawn at the top of the left atrium) \nb Fmax = maximal thickness of pleural tumor along the ﬁ  ssures measured on sagittal images",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 25
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_25",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nPleural Mesothelioma TNM Deﬁ  nitions–9th Edition\n1. Wolf AS, Eisele M, Giroux DJ, et al. The International Association for the Study of Lung Cancer pleural mesothelioma staging \nproject: Expanded database to inform revisions in the ninth edition of the TNM classification of pleural mesothelioma. J Thorac \nOncol. 2024;S1556-0864.\n2. Gill RR, Nowak AK, Giroux DJ, et al. The International Association for the Study of Lung Cancer mesothelioma staging \nproject: Proposals for revisions of the “T” descriptors in the forthcoming ninth edition of the TNM classification for pleural \nmesothelioma. J Thorac Oncol. 2024;S1556-0864.\n3. Bille AR, Ripley RT, Giroux DJ, et al. Proposals for the N descriptors in the forthcoming 9th edition of the TNM classification for \npleural mesothelioma. J Thorac Oncol. in press 2024.\n4. Kindler HL, Rosenthal A, Giroux DJ, et al. The IASLC Mesothelioma staging project: Proposals for the M descriptors in the \nforthcoming ninth edition the TNM classification for pleural mesothelioma. J Thorac Oncol., in press 2024.\n5. Nowak AK, Giroux DJ, Eisele M, et al. The IASLC Pleural Mesothelioma Staging Project: Proposal for revision of the TNM stage \ngroupings in the forthcoming ninth edition of the TNM classification for pleural mesothelioma. J Thorac Oncol, in press 2024.N0 N1 N2\nT1 I II IIIA\nT2 II IIIA IIIA\nT3 IIIA IIIA IIIA\nT4 IIIB IIIB IIIB\nM1 IV IV IVPleural Mesothelioma TNM Stages–9th EditionN Category Clinical (cN) and pathologic (pN) N \ndescriptors\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastases to ipsilateral intrathoracic \nlymph nodes (includes ipsilateral broncho-\npulmonary, hilar, subcarinal, paratracheal, \naortopulmonary, para-esophageal, peridia-\nphragmatic, pericardial fat pad, intercostal, \nand internal mammary nodes)\nN2 Metastases to contralateral lymph nodes. \nMetastases to ipsilateral or contralateral \nsupraclavicular lymph nodesM Category Clinical M descriptor (cM)\nM0 No distant metastasis\nM1 Distant metastasis present",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 26
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_26",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nCancer of the Esophagus and Esophagogastric Junction\n9th Edition\nNinth edition TNM categories. T is categorized as Tis: high-grade dysplasia; T1: cancer invades \nlamina propria, muscularis mucosae, or submucosa and is subcategorized into T1a (cancer \ninvades lamina propria or muscularis mucosae) and T1b (cancer invades submucosa); T2: cancer \ninvades muscularis propria; T3: cancer invades adventitia; T4, cancer invades local structures and \nis subcategorized as T4a: cancer invades adjacent structures such as pleura, pericardium, azygos \nvein, diaphragm, or peritoneum and T4b: cancer invades major adjacent structures such as aorta, \nvertebral body, or trachea. N is categorized as N0: no regional lymph node metastasis; N1, regional \nlymph node metastases involving 1 to 2 nodes; N2, regional lymph node metastases involving 3 to \n6 nodes; and N3, regional lymph node metastases involving 7 or more nodes. M is categorized as \nM0: no distant metastasis; and M1: distant metastasis. \n1. AJCC Cancer Staging Manual. 8th ed. Amin MB, Edge S, Greene FL, et al., eds. New York: Springer, 2017.\n2. TNM Classification of Malignant Tumours, 8th Edition. Brierley JD, Gospodarowicz MK, Wittekind C, eds. London: Wiley, 2016. \n3. Rice TW, Ishwarran H, Ferguson MK, et al. Cancer of the esophagus and esophageal junction: An 8th edition staging primer. \nJ Thorac Oncol. 2016; 12(1):36-42.\nCopyright ©2016 Cleveland Clinic Foundation, courtesy of Thomas W. Rice, MD.",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 27
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_27",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nCancer of the Esophagus and Esophagogastric Junction\n9th Edition\nT Category Descriptor\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma in situ/high-grade dysplasia\nT1 Tumor invades lamina propria, muscularis mucosa, or submucosa\nT1a Tumor invades lamina propria or muscularis mucosa\nT1b Tumor invades submucosa\nT2 Tumor invades muscularis propria\nT3 Tumor invades adventitia\nT4 Tumor invades adjacent structures\nT4a Tumor invades pleura, pericardium, azygos vein, diaphragm, or peritoneum (resectable)\nT4b Tumor invades other adjacent structures such as aorta, vertebral body, or trachea (non-resectable)\nN Category Descriptor\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in 1 - 2 regional lymph nodes\nN2 Metastasis in 3 - 6 regional lymph nodes\nN3 Metastasis in 7 or more regional lymph nodes\nM Category Descriptor\nM0 No distant metastasis\nM1 Distant metastasisTNM Deﬁ  nitions",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 28
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_28",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nCancer of the Esophagus and Esophagogastric Junction\n9th Edition\nCopyright ©2016 Cleveland Clinic Foundation, courtesy of Thomas W. Rice, MD.\nCA BLymph Node Map",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 29
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_29",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nCancer of the Esophagus and Esophagogastric Junction\n9th Edition\n1. AJCC Cancer Staging Manual. 8th ed. Amin MB, Edge S, Greene FL, et al., eds. New York: Springer, 2017.\n2. TNM Classification of Malignant Tumours, 8th Edition. Brierley JD, Gospodarowicz MK, Wittekind C, eds. London: Wiley, 2016.\n3. Rice TW, Ishwarran H, Ferguson MK, et al. Cancer of the esophagus and esophageal junction: An 8th edition staging primer. \nJ Thorac Oncol. 2016; 12(1):36-42.\nCopyright ©2016 Cleveland Clinic Foundation, courtesy of Thomas W. Rice, MD.Regional lymph node stations for staging esophageal cancer from le/f_t   (A), right (B), and anterior \n(C). 1R: Right lower cervical paratracheal nodes, between the supraclavicular paratracheal space \nand apex of the lung. 1L: Le/f_t   lower cervical paratracheal nodes, between the supraclavicular \nparatracheal space and apex of the lung. 2R: Right upper paratracheal nodes, between the \nintersection of the caudal margin of the brachiocephalic artery with the trachea and apex of \nthe lung. 2L: Le/f_t   upper paratracheal nodes, between the top of the aortic arch and apex of the \nlung. 4R: Right lower paratracheal nodes, between the intersection of the caudal margin of the \nbrachio cephalic artery with the trachea and cephalic border of the azygos vein. 4L: Le/f_t   lower \nparatracheal nodes, between the top of the aortic arch and the carina. 7: Subcarinal nodes, \ncaudal to the carina of the trachea. 8U: Upper thoracic paraesophageal lymph nodes, from the \napex of the lung to the tracheal bifurcation. 8M: Middle thoracic paraesophageal lymph nodes, \nfrom the tracheal bifurcation to the caudal margin of the inferior pulmonary vein. 8Lo: Lower \nthoracic paraesophageal lymph nodes, from the caudal margin of the inferior pulmonary vein \nesophagogastric junction. 9R: Pulmonary ligament nodes, within the right inferior pulmonary \nligament. 9L: Pulmonary ligament nodes, within the le/f_t   inferior pulmonary ligament. 15: \nDiaphragmatic nodes, lying on the dome of the diaphragm and adjacent to or behind its crura. \n16: Paracardial nodes, immediately adjacent to the gastroesophageal junction. 17: Le/f_t   gastric \nnodes, along the course of the le/f_t   gastric artery. 18: Common hepatic nodes, immediately on the \nproximal common hepatic artery. 19: Splenic nodes, immediately on the proximal splenic artery. \n20: Celiac nodes, at the base of the celiac artery. Cervical periesophageal level VI and level VII \nlymph nodes are named as per the head and neck map. Lymph Node Legend",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 30
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_30",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nCancer of the Esophagus and Esophagogastric Junction\n9th Edition\nExact measurements depend on body size and height. Location of cancer primary site is defined by \ncancer epicenter. Cancers involving the esophagogastric junction (EGJ) that have their epicenter within \nthe proximal 2 cm of the cardia (Siewert types I/II) are to be staged as esophageal cancers. Cancers whose \nepicenter is more than 2 cm distal from the EGJ, even if the EGJ is involved, will be staged using the \nstomach cancer TNM and stage groups.\nKey: LES, lower esophageal sphincter; UES, upper esophageal sphincter. \nRice TW, Ishwarran H, Ferguson MK, et al. Cancer of the esophagus and esophageal junction: An 8th edition staging primer. \nJ Thorac Oncol. 2016; 12(1):36-42.\nCopyright ©2016 Cleveland Clinic Foundation, courtesy of Thomas W. Rice, MD.Location of Esophageal Cancer Primary Site",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 31
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_31",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nCancer of the Esophagus and Esophagogastric Junction\n9th Edition\nClinical Stage for Squamous Cell Carcinoma of the Esophagus and the Esophagogastric Junction (cTNM)\nStage 0 Tis N0 M0\nStage I T1 N0, N1 M0\nStage II T2 N0, N1 M0\nT3 N0 M0\nStage III T1, T2 N2 M0\nT3 N1, N2 M0\nStage IVA T4a, T4b N0, N1, N2 M0\nAny T N3 M0\nStage IVB Any T Any N M1\nClinical Stage for Adenocarcinoma of the Esophagus and the Esophagogastric Junction (cTNM)\nStage 0 Tis N0 M0\nStage I T1 N0 M0\nStage IIA T1 N1 M0\nStage IIB T2 N0 M0\nStage III T2 N1 M0\nT3, T4a N0, N1 M0\nStage IVA T1-T4a N2 M0\nT4b N0, N1, N2 M0\nAny T N3 M0\nStage IVB Any T Any N M1\n1. Rice TW, Ishwaran H, Blackstone EH, et al. Recommendations for clinical staging (cTNM) of cancer of the esophagus and \nesophagogastric junction for the 8th edition AJCC/UICC staging manuals. Dis Esophagus. 2016;7:913-19.\n2. Rice TW, Apperson-Hansen C, DiPaola LM, et al. Worldwide Esophageal Cancer Collaboration: Clinical staging data. Dis \nEsophagus. 2016;7:707-14.\n3. Rice TW, Ishwarran H, Ferguson MK, et al. Cancer of the esophagus and esophageal junction: An 8th edition staging primer. J \nThorac Oncol. 2016; 12(1):36-42.Clinical Stage Groups (cTNM)",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 32
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_32",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nCancer of the Esophagus and Esophagogastric Junction\n9th Edition\nRice TW, Ishwaran H, Hofstetter WL, et al. Recommendations for pathologic staging (pTNM) of cancer of the esophagus and \nesophagogastric junction for the 8th edition AJCC/UICC staging manuals. Dis Esophagus. 2016;7:897-905.Pathologic Stage for Cancers of the Esophagus and the Esophagogastric Junction (pTNM)\nStage 0 Tis N0 M0\nStage IA T1a N0 M0\nStage IB T1b N0 M0\nStage IIA T2 N0 M0\nStage IIB T1 N1 M0\nT3 N0 M0\nStage IIIA T1 N2 M0\nT2 N1 M0\nStage IIIB T2 N2 M0\nT3 N1, N2 M0\nT4a N0, N1 M0\nStage IVA T4a N2 M0\nT4b Any N M0\nAnyT T3 M0\nStage IVB AnyT Any N M1\nPathologic stage is similar for both squamous cell carcinoma and adenocarcinoma.Pathologic Stage Groups (pTNM)",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 33
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_33",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nCancer of the Esophagus and Esophagogastric Junction\n9th Edition\nRice TW, Ishwaran H, Kelsen DP, et al. Recommendations for neoadjuvant pathologic staging (ypTNM) of cancer of the \nesophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. Dis Esophagus. 2016;29(8):906-912.Pathologic Stage After Neoadjuvant Therapy for Cancers of the Esophagus and the Esophagogastric Junction (ypTNM)\nStage T N M\nStage I T0-2 N0 M0\nStage II T3 N0 M0\nStage IIIA T0-2 N1 M0\nStage IIIB T3 N1 M0\nT0-3 N2 M0\nT4a N0 M0\nStage IVA T4a N1-2 M0\nT4a NX M0\nT4b N0-2 M0\nAny T N3 M0\nStage IVB Any T Any N M1\nypStage is also identical for both histopathologic cell types.Postneoadjuvant Pathologic Stage Groups (ypTNM)",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 34
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_34",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nCT Atlas–9th Edition\nRusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P. The IASLC lung cancer staging project. A proposal \nfor a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac \nOncol. 2009; 4: 568-577.\nFigure. Courtesy of International Association for the Study of Lung Cancer. Permission must be requested and granted before \nphotocopying or reproducing this material for distribution. Copyright ©2024 Aletta Ann Frazier, MD.LtSPV – left superior pulmonary vein\nmPA – main pulmonary artery\nRtInV – right innominate vein\nRtMB – right mainstem bronchus\nRtPA – right pulmonary artery\nLtPA – left pulmonary artery\nSVC – superior vena cava\nT – tracheaAbbreviations:\nAo– aorta\nAz – azygos vein\nEso – esophagus\nInV – innominate vein\nLLLB – le/f_t   lower lobe bronchus\nLtInV – le/f_t   innominate vein\nLtMB – le/f_t   mainstem bronchus\nLtPA – le/f_t   pulmonary artery\nLtSCA – le/f_t   subclavian artery\nAxial #3 Axial #2 Axial #1",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 35
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_35",
    "text": "INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER\nCT Atlas–9th Edition\nAo– aorta\nAz – azygos vein\nEso – esophagus\nInV – innominate vein\nLLLB – le/f_t   lower lobe bronchus\nLtInV – le/f_t   innominate vein\nLtMB – le/f_t   mainstem bronchus\nLtPA – le/f_t   pulmonary artery\nLtSCA – le/f_t   subclavian artery\nLtSPV – le/f_t   superior pulmonary vein\nmPA – main pulmonary artery\nRtInV – right innominate vein\nRtMB – right mainstem bronchus\nRtPA – right pulmonary artery\nLtPA – le/f_t   pulmonary artery\nSVC – superior vena cava\nT – tracheaAbbreviations:\ncricoid cartilage\nmanubrium\nlevel of\ncarinacricoid cartilage\nmanubrium\nlevel of\ncarina\nlevel of\nbronchus\nintermedius\ncricoid \ncartilage\ncarina\nbronchus\nintermediuslower lobe\nbronchusmanubrium/\napexSagittal Le/f_t  Sagittal Right\nCoronal",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 36
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_36",
    "text": "2021 WHO Classification\nLung Adenocarcinoma in\nResected SpecimensConquering Lung & Thoracic Cancers\nWorldwide in the 21st Century\nInvasive Non-Mucinous Lung Adenocarcinoma\nA \n C \n E \nB \n D \n F \nFigure 1. A. Macroscopic image of a subpleural tumour showing a solid component superiorly corresponding to invasive \nadenocarcinoma and a more ill-defined component inferiorly corresponding to a lepidic/non-invasive component. B. Lepidic \npattern adenocarcinoma. C. Papillary pattern with central fibrovascular cores. D. Acinar Pattern. E. Micropapillary pattern lacking \nfibrovascular cores. F. Solid pattern.\nReprinted with permission from WHO Classification of Tumours Editorial Board. Thoracic tumours. Lyon: IARC; 2021.Figure 2. Pie chart showing \nthe proportion of oncogenic \ndriver mutations nonmucinous \nadenocarcinoma of the lung from \neastern Asia and USA/Europe.Table 1. Grading of resected early-stage invasive non-mucinous lung adenocarcinoma based on histological patterns.\nGrade Differentiation Patterns\n1 Well differentiated Lepidic-predominant with no or < 20% high-grade pattern\n2 Moderately differentiated Acinar or papillary-predominant with no or < 20% high-grade pattern\n3 Poor differentiated Any tumour with ≥ 20% high-grade pattern (solid, micropapillary, cribriform, or complex \nglandular patterna)\naFused glands or single cells infiltrating in a desmoplastic stroma.",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 37
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_37",
    "text": "Invasive Mucinous Adenocarcinoma\nA \n B \nFigure 5.     \nA.  CT showing diffuse bilateral airspace \nand ground-glass opacity with nodular \ncomponents.\nB.  Macroscopic image shows a poorly \ndefined tumour with a soft mucoid \nappearance.\nC.  Pie chart of molecular alterations in \ninvasive mucinous adenocarcinomas.\nD.  Microscopically invasive mucinous \nadenocarcinoma shows columnar cells \nwith abundant apical intracytoplasmic \nmucin and small basally oriented \nnuclei with minimal cytological atypia \ngrowing.C \n D \nMinimally Invasive Adenocarcinoma\nA \n B \nFigure 4. A. CT scan showing part-solid nodule (circle) that is mostly ground-glass, with a small solid component measuring < 5 \nmm B. Microscopically a lepidic-predominant tumour with a total size <30 mm and an invasive area of 4mm. The tumour mostly \nshows a lepidic pattern of growth (top and right), with  a nodule of invasive adenocarcinoma (bottom left).  Adenocarcinoma In Situ\nFigure 3. A circumscribed proliferation of \nmalignant cells along the existing alveolar \nframework without invasive growth. 2021 WHO Classification\nLung Adenocarcinoma in\nResected SpecimensConquering Lung & Thoracic Cancers\nWorldwide in the 21st Century\nDiagnostic Features of Adenocarcinoma In Situ\n• A small localized tumour (≤ 30 mm)\n• Pure lepidic growth\n• No stromal, vascular, or pleural invasion\n• No pattern of invasive adenocarcinoma (e.g. acinar, papillary, micropapillary, \nsolid, colloid, enteric, fetal, or invasive mucinous adenocarcinoma)\n• No spread through airspaces\n• Cell type mostly non-mucinous (type II pneumocytes or club cells) but very \nrarely may be mucinous (tall columnar cells with basal nuclei and abundant \ncytoplasmic mucin, sometimes resembling goblet cells)\n• Nuclear atypia is inconspicuous\n• Septal widening with sclerosis/elastosis is common, particularly in non-\nmucinous adenocarcinoma in situ.",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 38
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_38",
    "text": "2021 WHO Classification\nMesothelioma\nConquering Lung & Thoracic Cancers\nWorldwide in the 21st Century\nMesothelioma in situ\nA preinvasive single-layer surface proliferation of neoplastic mesothelial cells.\n•  No thorascopic or imaging \nevidence of tumor\n•  History of recurrent pleural \neffusions\n•  Loss of BAP1 and/or MTAP  \nby IHC and/or CDKN2A  \nhomozygous deletion by FISHMesothelioma in situ BAP1 loss\nDiffuse Mesothelioma\nDiffuse plural thickening by a malignant neoplasm with epithelioid, sarcomatoid, or biphasic histology\nDiffuse epithelioid mesothelioma:\n• May appear cytologically bland \nor show marked atypia\n• A variety of architectural \npatterns, cytologic and stromal \nfeatures may occur, some with \nprognostic significance\n• Epithelioid mesothelioma \nshould also be graded\nTubulopapillary growth Solid growth\nDiffuse sarcomatoid mesothelioma:\n• Characterized by spindle cells \narranged in fasicles or in \nhaphazard patterns. \n• Desmoplastic mesothelioma is \ncharacterized by spindled cells \nwith minimal atypia arranged in \na patternless pattern in dense \nhyalinized stroma\nSarcomatoid mesothelioma Desmoplastic mesothelioma\nBiphasic mesothelioma with epitheli-\noid and sarcomatoid components\nTransitional morphology shows features \nin between epithelioid and sarcomatoid.  \nReticulin stains (right) show fibers \nsurrounding each cell as opposed to \ngroups of cells as in epithelioid meso-\nthelioma, may be helpful in some cases.Diffuse biphasic mesothelioma:\n• Composed of both epithelioid \nand sarcomatoid morphology;\n• ≥ 10% of each component \nshould be present in resection \nspecimens. \n• Areas of transitional \nmorphology should be \nconsidered sarcomatoid",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 39
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_39",
    "text": "2021 WHO Classification\nDiffuse Pleural Mesothelioma\nConquering Lung & Thoracic Cancers\nWorldwide in the 21st Century\nHistological Classification of Diffuse Pleural Mesothelioma\nType Description Patterns/features Favorable Unfavorable Reporting\nEpithelioid \nmesotheliomaComposed of round \nepithelioid cells, usually \nwith cohesive architec -\nture, but single cells \nwithin a fibrous stroma \nmay also be seenArchitectural patterns:\nTubulopapillary\nTrabecular\nAdenomatoid\nSolid\nMicropapillary\nCytological features:\nRhabdoid\nDeciduoida\nSmall cella\nClear cella\nSignet ringa\nLymphohistiocytoid\nPleomorphic\nStromal features:\nMyxoidArchitectural patterns:\nTubulopapillary\nTrabecular\nAdenomatoid\nCytological features:\nLymphohistiocytoid\nLow nuclear gradea\nStromal features:\nMyxoid (if predominant, \ni.e. when ≥ 50% of \ntumor with < 50% solid \npattern contains myxoid \nstroma)Architectural patterns:\nSolid (≥ 50%)\nMicropapillary\nCytological features:\nRhabdoid\nPleomorphic\nLow nuclear gradeb\nNecrosis:\n(included in grading)Grade (high or \nlow), architec -\ntural patterns \npresent (and in \ndefinitive resec -\ntion specimens \nsuch as EPD \nand EPP , \npercentages of \neach pattern; \nfor all other \nspecimens, \nindicate “with \n... patterns/\nfeatures”)\nSarcomatoid \nmesothelioma, \nincluding\ndesmoplastic \npatternComposed of elongated/\nspindle cells (> 2 times \nlonger than wide) ar -\nranged in solid sheets or \nwithin a fibrous stromaCytological features:\nLymphohistiocytoid\nTransitional\nPleomorphic\nStromal features:\nDesmoplastic\nWith heterologous dif -\nferentiationCytological features:\nLymphohistiocytoidCytological features:\nTransitional\nBiphasic \nmesotheliomaShowing both epithelioid \nand sarcomatoid com -\nponents (in definitive \nresection specimens, \nnamely EPD and EPP , ≥ \n10% of each component \nis required for diagno -\nsis); for smaller samples, \nincluding biopsy and \ncytology specimens, the \ndiagnosis of biphasic \nmesothelioma can be \nrendered regardless of \npercentages of each \ncomponent presentPercentage of \neach compo -\nnent should \nbe reported \nregardless of \nspecimen type\nGrading of Epithelial Mesothelioma\nNuclear grade:\nNuclear atypia score:  _____   1 for mild, 2 for moderate, 3 for severe\nMiotic count score:  _____   1 for low (≤1 mitosis/2mm2), 2 for intermediate (2-4 mitoses/2mm2), \n          3 for high (≥ 5 mitoses/2mm2)\nSum:  _____   2 or 3 = nuclear grade I, 4 or 5 = nuclear grade II, 6 = nuclear grade III\nNecrosis: present/absent\nOverall tumor grade:\nLow grade = nuclear grades I and II without necrosis\nHigh grade = nuclear grades II with necrosis, nuclear grade III with or without necrosis\nReprinted with permission from WHO Classification of Tumours Editorial Board. Thoracic tumours. Lyon: IARC; 2021.",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 40
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_40",
    "text": "2021 WHO Classification\nSquamous Cell Carcinoma\n(SQCC)Conquering Lung & Thoracic Cancers\nWorldwide in the 21st Century\nA malignant epithelial tumour characterized by the presence of keratinization,\nintercellular bridges, or immunohistochemical markers of squamous cell differentiation\nKeratinizing squamous cell \ncarcinoma with formation of \nkeratin pearls (left) and on cytology \nspecimen showing isolated \nmalignant cells with bizarrely \nshaped tadpole-appearance and \nkeratinized cytoplasm (right).\nKeratinization with pearl formation Keratinizing tumor cells (cytology)\nNon-keratinizing squamous \ncell carcinoma with tumor cells \ngrowing in solid pattern (left), no \nkeratinization and diffuse strongly \npositive nuclear p40 staining by \nimmunohistochemistry (right).\nCarcinoma with solid growth pattern P40 immunostain\nBasaloid squamous cell \ncarcinoma with cells showing \nscant cytoplasm, lobular growth \npattern and peripheral palisading \n(left), and diffuse p40 staining by \nimmunohistochemistry. Abrupt \nkeratinization and intercellular \nbridges may be seen (right).\nSolid carcinoma with lobular pattern Intercellular bridges\nSquamous dysplasia (left) and \ncarcinonoma in situ (right) are \npre-invasive lesions of squamous cell \ncarcinoma arising in the bronchial \nepithelium. They show a continuum \nof morphologically recognizable \nneoplastic histological changes \nassociated with accumulation of \nsomatic genetic alterations\nSevere dysplasia Squamous carcinoma in situ\nReprinted with permission from WHO Classification of Tumours Editorial Board. Thoracic tumours. Lyon: IARC; 2021.",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 41
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_41",
    "text": "Diagnostic Criteria for Squamous Dysplasia and Squamous Carcinoma in Situ\nAbnormality Thickness Cell Size Maturation/Orientation Nuclei\nMild  \ndysplasiaMildly \nincreasedMildly increased\nMild anisocytosis and  \npleomorphismContinuous progression of maturation \nfrom base to luminal surface\nBasilar zone expanded, with cellular \ncrowding in the lower third of \nepithelium\nDistinct intermediate (prickle cell) \nzone present\nSuperficial flattening of epithelial cellsMild variation of N:C ratio\nFinely granular chromatin\nMinimal angulation\nNucleoli inconspicuous or absent\nNuclei vertically oriented in lower third\nMitoses absent or very rare\nModerate \ndysplasiaModerately \nincreasedMildly increased\nCells often small\nMay have moderate \nanisocytosis and  \npleomorphismPartial progression of maturation from \nbase to luminal surface\nBasilar zone expanded, with cellular \ncrowding in the lower two thirds of \nepithelium\nIntermediate zone confined to upper \nthird of epithelium\nSuperficial flattening of epithelial cellsModerate variation of N:C ratio\nFinely granular chromatin\nAngulations, grooves, and lobulations \npresent\nNucleoli inconspicuous or absent\nNuclei vertically oriented in lower two thirds\nMitotic figures present in lower third\nSevere  \ndysplasiaMarkedly \nincreasedMarkedly increased\nMay have marked  \nanisocytosis and  \npleomorphismLittle progression of maturation from \nbase to luminal surface\nBasilar zone expanded, with cellular \ncrowding well into the upper third of \nepithelium\nIntermediate zone greatly attenuated\nSuperficial flattening of epithelial cellsN:C ratio often high and variable\nChromatin coarse and uneven\nNuclear angulations and folding prominent\nNucleoli frequently present and \nconspicuous\nNuclei vertically oriented in lower two thirds\nMitotic figures present in lower two thirds\nCarcinoma \nin situMay or \nmay not be \nincreasedMay be markedly  \nincreased\nMay have marked \nanisocytosis and \npleomorphismNo progression of maturation from \nbase to luminal surface; epithelium \ncan be inverted, with little change in \nappearance\nBasilar zone expanded, with cellular \ncrowding throughout the epithelium \nIntermediate zone absent\nSurface flattening confined to the \nmost superficial cellsN:C ratio often high and variable\nChromatin coarse and uneven\nNuclear angulations and folding prominent\nNucleoli may be present or inconspicuous\nNo consistent orientation of nuclei in \nrelation to epithelial surface\nMitotic figures present through full \nthicknessSquamous Dysplasia and  \nCarcinoma-In SituConquering Lung & Thoracic Cancers\nWorldwide in the 21st Century\nSquamous cell carcinoma in situ.\nWhite-light reflective bronchoscopy (A) and \nautofluorescence bronchoscopy (B) of a squamous cell \ncarcinoma in situ with microinvasion in the trachea.  \nThere was no light abnormality on the white-light \nreflectance bronchoscopy examination. A plaque-like \nlesion on white-light reflectance bronchoscopy (C) and \noptical coherence tomography (D) showing invasion of  \nthe tumor through the basal membrane.",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 42
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_42",
    "text": "2021 WHO Classification\nSmall Biopsy and\nCytology SamplesConquering Lung & Thoracic Cancers\nWorldwide in the 21st Century\nGeneral Principles\n• Minimize stains to maximize tissue for molecular testing\n• Cut tissue block as sparingly as possible\n• Obtain unstained slides for molecular at time of cutting block for IHC\n• Use limited panel of IHC (i.e TTF-1 and P40): reduces NSCC-NOS  \nfrom ~40% to <10%.\n• Molecular testing, if clinically appropriate, can be performed on  \nremaining tissueTravis WD, Brambilla E, Burke \nAP , Marx A, Nicholson AG. WHO \nClassification of Tumours of the \nLung, Pleura, Thymus and Heart. \nLyon: IARC; 2015.”A. Adenocarcinoma (ADC) Cytology A. Squamous Cell Carcinoma (SQCC) \nCytology\nB. Nonsmall Cell Carcinoma (NSCC), \nFavor ADCB. NSCC, Favor SQCC\nC. TTF-1 C. P40\na) Cytology shows cluster of tumor \ncells around a small lumen with focal \nintracytoplasmic mucin, (b) NSCC, favor \nADC; solid but no glandular pattern, \n(c) TTF-1 is positivea) Cytology shows pleomorphic and \nkeratinized tumor cells including a \ntadpole cell, (b) NSCC favor squamous \ncell carcinoma (c) P40 is positive (TTF-1 \nwas negative) ALK Rearranged\nAdenocarcinoma\nA) Cribriform Pattern\nB) ALK IHC \nC) ALK FISH",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 43
    }
  },
  {
    "id": "Staging Cards 9th Edition 2024_chunk_43",
    "text": "Terminology and Criteria for\nCommon Lung Cancers in\nSmall Biopsies and Cytology Conquering Lung & Thoracic Cancers\nWorldwide in the 21st Century\nSmall Biopsy/Cytology \nTerminology Morphology/Stains2021 WHO Classification in  \nResection Specimens\nAdenocarcinoma (describe \nidentifiable patterns present)Morphological adenocarcinoma \npatterns clearly presentAdenocarcinoma (Predominant \npattern) Lepidic, Acinar, Papillary, \nSolid, Micropapillary\nAdenocarcinoma with lepidic pattern \n(if pure, add note: an invasive \ncomponent cannot be excluded)Lepidic (nonmucinous)\nMinimally invasive adenocarcinoma, \nadenocarcinoma in situ or an invasive \nadenocarcinoma with a lepidic \ncomponent\nInvasive mucinous adenocarcinoma \n(describe patterns present; if pure \nlepidic pattern, use term mucinous \nadenocarcinoma with lepidic pattern \nAdenocarcinoma with colloid features\nAdenocarcinoma with fetal features\nAdenocarcinoma with enteric featuresInvasive mucinous adenocarcinoma\nColloid adenocarcinoma\nFetal adenocarcinoma\nEnteric adenocarcinoma\nNon-small cell carcinoma, favor \nadenocarcinomaMorphologic adenocarcinoma patterns \nnot present, but supported by special \nstains, i.e. +TTF-1Adenocarcinoma (solid pattern may \nbe just one component of the tumor)b \nSquamous cell carcinoma Morphologic squamous cell patterns \nclearly presentSmall cell carcinoma\nNon-small cell carcinoma, favor \nsquamous cell carcinomaMorphologic squamous cell patterns \nnot present, but supported by stains \ni.e. +p40Squamous cell carcinoma, \n(nonkeratinizing pattern may be just \none component of the tumor) \nNon-small cell carcinoma, not \notherwise specified NSCC-NOSNo clear adenocarcinoma, squamous \nor neuroendocrine morphology or \nstaining patternLarge cell carcinoma\nSmall cell carcinoma Small cell carcinoma\nNon-small cell carcinoma with \nneuroendocrine (NE) morphology and \npositive NE markers, possible LCNECLarge cell neuroendocrine carcinoma\n(LCNEC)\nMorphologic squamous cell and \nadenocarcinoma patterns present:\nNon-small cell carcinoma, NOS, \n(comment that adenocarcinoma \nand squamous components are \npresent and this could represent \nadenosquamous carcinoma).Adenosquamous carcinoma\nReprinted with permission from WHO Classification of Tumours Editorial Board. Thoracic tumours. Lyon: IARC; 2021.",
    "metadata": {
      "source": "Staging Cards 9th Edition 2024",
      "type": "staging",
      "page": 44
    }
  }
]